Subclinical Hypothyroidism and Chronic Inflammation in PCOS

Sponsor
Jagiellonian University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05842096
Collaborator
(none)
300
1
2
18
16.6

Study Details

Study Description

Brief Summary

Chronic inflammation in polycystic ovary syndrome (PCOS) may be the result of dysregulation of cytokine production (due to insulin resistance, excess visceral fat and hyperandrogenemia), i.e., overproduction of pro-inflammatory factors (e.g. TNF, IL-1, IL-6) in relation to anti-inflammatory ones (IL-10). This condition may be an important link between obesity and insulin resistance, which is crucial in the etiopathogenesis of the syndrome. However, it is not known whether it results from the tendency to accumulate adipose tissue or is a feature of the syndrome itself. Concomitant endocrinopathies, i.e. obesity, dyslipidemia, insulin resistance, diabetes and thyroid diseases, may additionally influence the activity of chronic inflammation. There is no data indicating the relationship between chronic inflammation and PCOS phenotypes, the severity of metabolic disorders, ovarian reserve and the influence of thyroid function on its activity in PCOS.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Measurement and comparison of leucocytosis and concentrations of CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha in both study arms
  • Diagnostic Test: Evaluation of the impact of subclinical hypothyroidism, with present/ absent antithyroid antibodies, on the balance between anti- and pro-inflammatory factors in women in both study arms
  • Diagnostic Test: Assessment of the impact of imbalance between anti- and pro-inflammatory factors in women with different PCOS and HPOD phenotypes on ovarian reserve indices
N/A

Detailed Description

The aim of the study is:
  1. to assess and compare serum concentrations of selected inflammatory markers (leucocytosis, CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha) in women with different phenotypes PCOS and hypothalamic-pituitary-ovarian axis dysfunction (HPOD) (control), ii) to evaluate the impact of subclinical hypothyroidism (defined as TSH>2.5 uIU/ml, fT3 3,1-6,80 pmol/l, fT4 12,0-22,0 pmol/l), with the presence and absence of circulating antithyroid antibodies (a-TPO and a-TG), on the balance between anti- and pro-inflammatory factors in women with different PCOS and HPOD phenotypes, iii) to assess the impact of imbalance between anti- and pro-inflammatory factors in women with different PCOS and HPOD phenotypes on ovarian reserve indices, expressed as FSH and AMH concentrations.

The study population will be characterized in terms of demographic (age, BMI), gynecological (age of first and last menstrual period, cycle length, history of reproductive organ surgeries, ultrasound measurements of endometrial width, ovarian volume) and obstetrics (pregnancies, childbirth, miscarriages) data. PCOS syndrome (and its phenotypes) will be recognized by the Rotterdam criteria. HPOD will be diagnosed according to WHO criteria. During hospitalization, blood samples will be collected for scheduled analyzes (30 ml of blood in total).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
300 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
prospective tertiary single-centre cohort studyprospective tertiary single-centre cohort study
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
The Influence of Subclinical Hypothyroidism on Chronic Inflammation Activity in Women With Different PCOS Phenotypes
Anticipated Study Start Date :
Jul 1, 2023
Anticipated Primary Completion Date :
Sep 30, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Polycystic ovary syndrome (PCOS)

Women meeting the Rotterdam-ESHRE-ASRM criteria for a diagnosis of PCOS

Diagnostic Test: Measurement and comparison of leucocytosis and concentrations of CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha in both study arms
A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare the above parameters of peripheral blood in both arms of the study

Diagnostic Test: Evaluation of the impact of subclinical hypothyroidism, with present/ absent antithyroid antibodies, on the balance between anti- and pro-inflammatory factors in women in both study arms
A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare blood levels of leukocytosis, CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha depending on the blood concentrations of TSH, a-TPO and a-TG in women in both study arms

Diagnostic Test: Assessment of the impact of imbalance between anti- and pro-inflammatory factors in women with different PCOS and HPOD phenotypes on ovarian reserve indices
A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare blood levels of leukocytosis, CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha and AMH, FSH in women in both study arms

Active Comparator: Hypothalamic-Pituitary-Ovarian Axis Dysfunction (HPOD)

Women meeting the WHO criteria for a diagnosis of HPOD

Diagnostic Test: Measurement and comparison of leucocytosis and concentrations of CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha in both study arms
A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare the above parameters of peripheral blood in both arms of the study

Diagnostic Test: Evaluation of the impact of subclinical hypothyroidism, with present/ absent antithyroid antibodies, on the balance between anti- and pro-inflammatory factors in women in both study arms
A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare blood levels of leukocytosis, CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha depending on the blood concentrations of TSH, a-TPO and a-TG in women in both study arms

Diagnostic Test: Assessment of the impact of imbalance between anti- and pro-inflammatory factors in women with different PCOS and HPOD phenotypes on ovarian reserve indices
A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare blood levels of leukocytosis, CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha and AMH, FSH in women in both study arms

Outcome Measures

Primary Outcome Measures

  1. Values of inflammation parameters - leukocytosis in peripheral blood in both study arms [up to 6 months]

    Measurement and comparison of leukocyte count (n/µL) in peripheral blood in both study arms

  2. Values of inflammation parameters - CRP in peripheral blood in both study arms [up to 6 months]

    Measurement and comparison of concentrations of CRP (mg/l) in peripheral blood in both study arms

  3. Values of inflammation parameters - procalcitonine in peripheral blood in both study arms [up to 6 months]

    Measurement and comparison of concentrations of procalcitonin (μg/l) in peripheral blood in both study arms

  4. Values of inflammation parameters - fibrinogen in peripheral blood in both study arms [up to 6 months]

    Measurement and comparison of concentrations of procalcitonin fibrinogen (g/l) in peripheral blood in both study arms

  5. Values of inflammation parameters - ferritin in peripheral blood in both study arms [up to 6 months]

    Measurement and comparison of concentrations of procalcitonin ferritin (μg/l) in peripheral blood in both study arms

  6. Values of inflammation parameters - IL-1 in peripheral blood in both study arms [up to 6 months]

    Measurement and comparison of concentrations of procalcitonin IL-1 (pg/ml) in peripheral blood in both study arms

  7. Values of inflammation parameters - IL-6 in peripheral blood in both study arms [up to 6 months]

    Measurement and comparison of concentrations of procalcitonin IL-6 (pg/ml) in peripheral blood in both study arms

  8. Values of inflammation parameters - IL-10 in peripheral blood in both study arms [up to 6 months]

    Measurement and comparison of concentrations of procalcitonin IL-10 (pg/ml) in peripheral blood in both study arms

  9. Values of inflammation parameters - TNF-alpha in peripheral blood in both study arms [up to 6 months]

    Measurement and comparison of concentrations of procalcitonin TNF-alpha (pg/ml) in peripheral blood in both study arms

Secondary Outcome Measures

  1. Correlation between the concentration of TSH (mIU/l) and the parameters of inflammation - leukocytosis in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of TSH (mIU/l) and inflammatory parameters: leukocyte count (n/µL)

  2. Correlation between the concentration of TSH (mIU/l) and the parameters of inflammation - CRP in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of TSH (mIU/l) and inflammatory parameters: CRP (mg/l)

  3. Correlation between the concentration of TSH (mIU/l) and the parameters of inflammation - procalcitonin in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of TSH (mIU/l) and inflammatory parameters: procalcitonin (μg/l)

  4. Correlation between the concentration of TSH (mIU/l) and inflammatory parameters: fibrinogen (μg/l) [up to 6 months]

    Evaluation of the correlation between the concentration of TSH (mIU/l) and inflammatory parameters: fibrinogen (g/l)

  5. Correlation between the concentration of TSH (mIU/l) and inflammatory parameters: ferritin (μg/l) [up to 6 months]

    Evaluation of the correlation between the concentration of TSH (mIU/l) and inflammatory parameters: ferritin (μg/l)

  6. Correlation between the concentration of TSH (mIU/l) and inflammatory parameters: il-1 [up to 6 months]

    Evaluation of the correlation between the concentration of TSH (mIU/l) and inflammatory parameters: iL-1 (pg/ml)

  7. Correlation between the concentration of TSH (mIU/l) and inflammatory parameters: il-6 [up to 6 months]

    Evaluation of the correlation between the concentration of TSH (mIU/l) and inflammatory parameters: iL-6 (pg/ml)

  8. Correlation between the concentration of TSH (mIU/l) and inflammatory parameters: il-10 [up to 6 months]

    Evaluation of the correlation between the concentration of TSH (mIU/l) and inflammatory parameters: iL-10 (pg/ml)

  9. Correlation between the concentration of TSH (mIU/l) and inflammatory parameters: TNF-alpha [up to 6 months]

    Evaluation of the correlation between the concentration of TSH (mIU/l) and inflammatory parameters: TNF-alpha (pg/ml)

  10. Correlation between the concentration of a-TPO (IU/ml) and the parameters of inflammation - leukocytosis in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: leukocyte count (n/µL)

  11. Correlation between the concentration of a-TPO (IU/ml) and the parameters of inflammation - CRP in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: CRP (mg/l)

  12. Correlation between the concentration of a-TPO (IU/ml) and the parameters of inflammation - procalcitonin in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: procalcitonin (μg/l)

  13. Correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: fibrinogen (μg/l) [up to 6 months]

    Evaluation of the correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: fibrinogen (μg/l)

  14. Correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: ferritin (μg/l) [up to 6 months]

    Evaluation of the correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: ferritin (μg/l)

  15. Correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: il-1 (pg/ml) [up to 6 months]

    Evaluation of the correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: il-1 (pg/ml)

  16. Correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: il-6 (pg/ml) [up to 6 months]

    Evaluation of the correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: il-6 (pg/ml)

  17. Correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: il-10 (pg/ml) [up to 6 months]

    Evaluation of the correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: il-10 (pg/ml)

  18. Correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: TNF-alpha (pg/ml) [up to 6 months]

    Evaluation of the correlation between the concentration of a-TPO (IU/ml) and inflammatory parameters: TNF -alpha (pg/ml)

  19. Correlation between the concentration of a-TG (IU/ml) and the parameters of inflammation - CRP in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: CRP (mg/l)

  20. Correlation between the concentration of a-TG (IU/ml) and the parameters of inflammation - leukocytosis in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: leukocyte count (n/µL)

  21. Correlation between the concentration of a-TG (IU/ml) and the parameters of inflammation - procalcitonin in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: procalcitonin (μg/l)

  22. Correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: fibrinogen (μg/l) [up to 6 months]

    Evaluation of the correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: fibrinogen (μg/l)

  23. Correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: il-1 (pg/ml) [up to 6 months]

    Evaluation of the correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: il-1 (pg/ml)

  24. Correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: il-6 (pg/ml) [up to 6 months]

    Evaluation of the correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: il-6 (pg/ml)

  25. Correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: il-10 (pg/ml) [up to 6 months]

    Evaluation of the correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: il-10 (pg/ml)

  26. Correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: TNF-alpha (pg/ml) [up to 6 months]

    Evaluation of the correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: TNF-alpha (pg/ml)

  27. Correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: ferritin (μg/l) [up to 6 months]

    Evaluation of the correlation between the concentration of a-TG (IU/ml) and inflammatory parameters: ferritin (μg/l)

  28. Correlation between the concentration of AMH (pmol/l) and the parameters of inflammation - leukocytosis in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of AMH (pmol/l) and inflammatory parameters: leukocyte count (n/µL)

  29. Correlation between the concentration of AMH (pmol/l) and the parameters of inflammation - CRP in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of AMH (pmol/l) and inflammatory parameters: CRP (mg/l)

  30. Correlation between the concentration of AMH (pmol/l) and the parameters of inflammation - procalcitonin in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of AMH (pmol/l) and inflammatory parameters: procalcitonin (μg/l)

  31. Correlation between the concentration of AMH (pmol/l) and the parameters of inflammation - fibrinogen in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of AMH (pmol/l) and inflammatory parameters: fibrinogen (μg/l)

  32. Correlation between the concentration of AMH (pmol/l) and the parameters of inflammation - ferritin in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of AMH (pmol/l) and inflammatory parameters: ferritin (μg/l)

  33. Correlation between the concentration of AMH (pmol/l) and the parameters of inflammation - il-1 in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of AMH (pmol/l) and inflammatory parameters: il-1 (pg/ml)

  34. Correlation between the concentration of AMH (pmol/l) and the parameters of inflammation - il-6 in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of AMH (pmol/l) and inflammatory parameters: il-6 (pg/ml)

  35. Correlation between the concentration of AMH (pmol/l) and the parameters of inflammation - il-10 in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of AMH (pmol/l) and inflammatory parameters: il-10 (pg/ml)

  36. Correlation between the concentration of AMH (pmol/l) and the parameters of inflammation - TNF-alpha in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of AMH (pmol/l) and inflammatory parameters: TNF-alpha (pg/ml)

  37. Correlation between the concentration of FSH (IU/l) and the parameters of inflammation - leukocytosis in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of FSH (IU/l) and inflammatory parameters: leukocyte count (n/µL)

  38. Correlation between the concentration of FSH (IU/l) and the parameters of inflammation - CRP in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of FSH (IU/l) and inflammatory parameters: CRP (mg/l)

  39. Correlation between the concentration of FSH (IU/l) and the parameters of inflammation - procalcitonin in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of FSH (IU/l) and inflammatory parameters: procalcitonin (μg/l)

  40. Correlation between the concentration of FSH (IU/l) and the parameters of inflammation - fibrinogen in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of FSH (IU/l) and inflammatory parameters: fibrinogen (μg/l)

  41. Correlation between the concentration of FSH (IU/l) and the parameters of inflammation - ferritin in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of FSH (IU/l) and inflammatory parameters: ferritin (μg/l)

  42. Correlation between the concentration of FSH (IU/l) and the parameters of inflammation - il-1 in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of FSH (IU/l) and inflammatory parameters: il-1 (pg/ml)

  43. Correlation between the concentration of FSH (IU/l) and the parameters of inflammation - il-6 in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of FSH (IU/l) and inflammatory parameters: il-6 (pg/ml)

  44. Correlation between the concentration of FSH (IU/l) and the parameters of inflammation - il-10 in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of FSH (IU/l) and inflammatory parameters: il-10 (pg/ml)

  45. Correlation between the concentration of FSH (IU/l) and the parameters of inflammation - TNF-alpha in both arms of the study [up to 6 months]

    Evaluation of the correlation between the concentration of FSH (IU/l) and inflammatory parameters:TNF-alpha (pg/ml)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • age 18-45 years,

  • cycle length <21 days or > 35 days,

  • unsuccessful attempts to conceive for at least 12 months of regular intercourse with sonographically confirmed anovulation with excluded male, tubal and uterine infertility factors.

Exclusion Criteria:
  • absence of at least one ovary,

  • previously diagnosed thyroid disease

Contacts and Locations

Locations

Site City State Country Postal Code
1 Jagiellonian University Medical College, Department of Gynecology and Obstetrics Kraków Poland 31-501

Sponsors and Collaborators

  • Jagiellonian University

Investigators

  • Study Chair: Robert Jach, Prof., Ph.D., Jagiellonian University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Iwona Magdalena Gawron, Ph.D., Principal Investigator, Jagiellonian University
ClinicalTrials.gov Identifier:
NCT05842096
Other Study ID Numbers:
  • 1072.6120.292.2022
First Posted:
May 3, 2023
Last Update Posted:
May 3, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 3, 2023